RESUMO
From 1988 to 1992, 2479 volunteers were immunized by inactivated Meriones unguiculatus kidney cell (MUKC) vaccine. Their seroconversion rates of neutralizing antibody were about 90% after 3 doses of the vaccine. No side effects were found. The vaccine stored for 14 months at 4 degrees C still had good immunogenicity. It was shown that the vaccine was safe, effective and stable. Detailed observation was made in 75 volunteers. The results showed that the seroconversion rate by plaque reduction neutralization test in 3 doses group was higher than that in 2 doses group; but the results by reversed passive hemagglutination (RPHI), immunofluorescence assay (IFA) and ELISA were similar. Different immunization procedures (3 x 1 ml during 28 days or 3 x 1 ml during 60 days), injection routes (im or sc) and vaccine forms (containing adjuvants or not) showed no significant difference. If secondary immunization (one dose) was given one year after primary immunization, geometric mean titre of the neutralizing antibody was two fold higher than that after primary immunization.
Assuntos
Vírus Hantaan/imunologia , Febre Hemorrágica com Síndrome Renal/prevenção & controle , Vacinas Virais/imunologia , Animais , Anticorpos Antivirais/sangue , Técnicas de Cultura , Humanos , Imunização Secundária , Camundongos , Testes de Neutralização , Coelhos , Vacinação/métodos , Vacinas de Produtos Inativados/imunologiaRESUMO
Using the Z-10 strain of epidemic hemorrhagic fever virus (EHFV) as seed, and the primary cell of Meriones unguiculatus kidney tissue as incubation cell, a propiolactone inactivated epidemic hemorrhagic fever (EHF) vaccine was prepared, according to a similar procedure required for the production of biological products such as the Japanese B encephalitis vaccine. Besides the EHFV antigen detected by ELISA or reversed passive hemagglutination test (RPHA) as were used for the formalin inactivated vaccine, higher titres (1:128-1:1024) of EHFV hemagglutinin antigen was also detected in this EHFV vaccine. Immunization with twice intramuscular injection of this vaccine produced high titred (1:20-1:160) neutralizing antibody and low titred (1:10-1:20) hemagglutination antibody, in addition to the immunofluorescence (IF) and reversed passive hemagglutination inhibition (RPHI) antibodies. These results indicated an apparent difference in the immunogenicity between the beta-propiolactone and formalin inactivated EHF vaccines. With the approval of the Ministry of Health, human test is now underway in this laboratory.
